LATIFY & MOUNTAINEERING-03 Open at the UCD Cancer Trials Cluster

We are pleased to announce the opening of two new exciting trials at the UCD Cancer Trials Cluster clinical sites, St Vincent’s University Hospital and the Mater Misericordiae University Hospital. These trials, LATIFY and MOUNTAINEER-03, aim to find better ways of treating metastatic colorectal cancer and non-small cell lung cancer, two underserved groups of people.

We are accepting national referrals for both LATIFY and MOUNTAINEER-03. If you are interested in either of the below trials, please discuss these with your medical oncology teams.

MOUNTAINEER-03

The MOUNTAINEER-03 study is being done to find out if Tucatinib with other cancer drugs works better than standard of care. This study will also test what, if any, side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

This study is for people with HER2 positive colorectal cancer that is metastatic and cannot be treated with surgery.

Clinical Trial Registration: (opens in a new window)https://classic.clinicaltrials.gov/ct2/show/NCT05253651

LATIFY

The LATIFY study will compare the effectiveness and safety of a new drug combination (Ceralasertib and Durvalumab) with current standard of care (Docetaxel).

This study is for people with locally advanced and metastatic non-small cell lung cancer, whose disease has progressed after previous anti-PD-(L)1 therapy and platinum-based chemotherapy.

Clinical Trial Registration: (opens in a new window)https://classic.clinicaltrials.gov/ct2/show/NCT05450692

You can find an up-to-date list of all of our trials here.